# Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

> **NCT00727233** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 9 (actual)

## Conditions studied

- Neurofibromatosis Type I
- Plexiform Neurofibroma

## Interventions

- **DRUG:** Nexavar (BAY 43-9006) (Sorafenib)
- **DRUG:** Toxicity, Pharmacokinetics
- **DRUG:** Pharmacodynamics
- **DRUG:** Radiographic Evaluation
- **DRUG:** QOL assessment, Neuropsychological
- **DRUG:** Bony Toxicity

## Key facts

- **NCT ID:** NCT00727233
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07-08
- **Primary completion:** 2011-06-16
- **Final completion:** 2011-06-16
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00727233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00727233, "Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00727233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*